Sino Biopharmaceutical Ltd. financial statements, including revenue, expenses, profit, and loss
The total revenue of SBHMY for the last semiannual is 2.20 B USD, and it's 45.78% higher compared to the previous semiannual. The net income of H1 24 is 199.97 M USD.